WegovyvsSaxenda

Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.

Saxenda's active ingredient is liraglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centers, it increases feelings of fullness and reduces hunger, which tends to lower how many calories you eat. It also slows stomach emptying, so food stays in the stomach longer. Because liraglutide is relatively short-acting, it must be injected once every day, unlike newer once-weekly GLP-1 drugs.

In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.

In the pivotal SCALE Obesity and Prediabetes trial (NEJM, 2015), adults without diabetes lost a mean of 8.0% of body weight on liraglutide 3.0 mg versus 2.6% on placebo at 56 weeks. About 63% of liraglutide patients lost at least 5% of body weight (vs. 27% on placebo) and roughly 33% lost at least 10% (vs. 11% on placebo). However, in the head-to-head STEP 8 trial (JAMA, 2022), once-weekly semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% for daily liraglutide 3.0 mg over 68 weeks, more than double the effect. Individual results vary and depend heavily on combining the drug with diet and activity.

The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, typically mild-to-moderate and worst during the first weeks as the dose is increased. Headache, low blood sugar (especially in people with type 2 diabetes), increased heart rate, and injection-site reactions also occur. Serious but uncommon risks include acute pancreatitis, gallbladder disease (gallstones), and kidney problems from dehydration. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek urgent medical care for severe, persistent abdominal pain, signs of an allergic reaction, or a lump or swelling in the neck.

As of September 2026, Wegovy's list price is $1,349.02 per package, but cash-paying patients rarely pay that: NovoCare's self-pay price is $349/month for the 0.25–2.4 mg pens and $399/month for Wegovy HD 7.2 mg, and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Wegovy pill has separate self-pay pricing starting at $149/month. With commercial insurance that covers Wegovy, the manufacturer savings card can lower the copay further for eligible patients, but many plans — and most Medicare and Medicaid plans — still exclude weight-loss drugs. Verify pricing for your dose with NovoCare before starting.

As of 2026, Saxenda's cash price without insurance runs roughly $1,300 to $1,650 per month for a 30-day supply (five prefilled pens), varying by pharmacy. Pharmacy discount coupons (e.g., GoodRx) can cut this to around $370-$500. Insurance coverage is inconsistent, often requires prior authorization, and many commercial plans, plus Medicare, exclude weight-loss drugs entirely. Note that Novo Nordisk's $25 Saxenda Savings Card was discontinued for new enrollees in mid-2023, so it is no longer a reliable way to lower cost; uninsured patients with limited income may instead qualify for free medication through the Novo Nordisk Patient Assistance Program. A lower-cost generic liraglutide (from Teva) launched in the US in 2025 at roughly $1,165 per month, which may reduce out-of-pocket costs over time as availability expands.

Wegovy is FDA-approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) who also have a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. It is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease who are overweight or obese, and for adolescents aged 12 and older with obesity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with a known serious allergy to semaglutide or any Wegovy ingredient. It should not be used during pregnancy; because of semaglutide's long half-life, the label advises stopping at least 2 months before a planned pregnancy. Use cautiously, and under close supervision, with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems, or diabetic retinopathy. A clinician determines eligibility.

Saxenda is FDA-approved for adults with obesity (BMI 30 or higher) or with a BMI of 27 or higher plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, and for adolescents aged 12-17 who weigh more than 132 lbs (60 kg) and have obesity. It is meant to be used alongside a reduced-calorie diet and increased physical activity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), in pregnancy, and in people with a prior serious allergic reaction to liraglutide. It should not be combined with other GLP-1 medicines and is used cautiously in those with a history of pancreatitis or gallbladder disease. Your prescriber makes the final eligibility decision.